-
公开(公告)号:WO2009098697A1
公开(公告)日:2009-08-13
申请号:PCT/IL2009/000146
申请日:2009-02-08
申请人: Dexxon Ltd. , PENHASI, Adel , GAUCHMAN, Janina , SHAULI, Amanda , RUDERMAN, Marina , AVRAMOFF, Avi
IPC分类号: A61K9/32 , A61K9/48 , A61K31/165 , A61K31/519
CPC分类号: A61K9/2866 , A61K9/284 , A61K9/4808 , A61K31/165 , A61K31/519
摘要: Modified release formulations comprising at least one of modafinil and sildenafil, and combinations thereof, and a time-controlled delivery system coating.
摘要翻译: 包含莫达非尼和西地那非或其组合中的至少一种的调释释放制剂和时间控制的递送系统涂层。
-
公开(公告)号:WO2006103661A3
公开(公告)日:2007-06-28
申请号:PCT/IL2006000387
申请日:2006-03-27
发明人: PENHASI ADEL , RUDERMAN MARINA , GOMBERG MAXIM
IPC分类号: A61K9/14 , A61K9/16 , A61K9/20 , A61K9/22 , A61K9/24 , A61K9/26 , A61K9/28 , A61K9/30 , A61K9/32 , A61K9/36 , A61K9/48 , A61K9/52 , A61K9/54 , A61K9/56 , A61K9/58 , A61K9/62
CPC分类号: A61K31/00 , A61K9/2846 , A61K9/2866
摘要: A delayed onset controlled release formulation is provided in which controlled release of the active ingredient occurs preferentially in the lower gastrointestinal tract including the colon. The formulation supports a significantly higher bioavailability of the active ingredient in the body of the subject than can be achieved from the currently used conventional formulation, such that therapeutically significant plasma levels of statin are maintained for an extended period after administration. The formulation preferably features a core, over which an outer coating is layered. The core is optionally and preferably in the form of a tablet.
摘要翻译: 提供延迟发作控释制剂,其中活性成分的控制释放优先在包括结肠的下胃肠道中。 该制剂支持比目前使用的常规制剂可以实现的受试者体内活性成分显着更高的生物利用度,使得他汀在施用后长时间内维持治疗上显着的血浆水平。 制剂优选具有芯,其上层叠有外涂层。 核心是任选的,优选为片剂形式。
-
公开(公告)号:WO2006103661A2
公开(公告)日:2006-10-05
申请号:PCT/IL2006/000387
申请日:2006-03-27
发明人: PENHASI, Adel , RUDERMAN, Marina , GOMBERG, Maxim
IPC分类号: A61K9/56
CPC分类号: A61K31/00 , A61K9/2846 , A61K9/2866
摘要: A delayed onset controlled release formulation is provided in which controlled release of the active ingredient occurs preferentially in the lower gastrointestinal tract including the colon. The formulation supports a significantly higher bioavailability of the active ingredient in the body of the subject than can be achieved from the currently used conventional formulation, such that therapeutically significant plasma levels of statin are maintained for an extended period after administration. The formulation preferably features a core, over which an outer coating is layered. The core is optionally and preferably in the form of a tablet.
摘要翻译: 提供延迟发作控制释放制剂,其中活性成分的控制释放优先在包括结肠的下胃肠道中。 该制剂支持比目前使用的常规制剂可以实现的受试者体内活性成分显着更高的生物利用度,使得他汀在给药后长时间内维持治疗上显着的血浆水平。 制剂优选具有芯,其上层叠有外涂层。 芯可选地优选为片剂的形式。
-
-